For example, the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial, in which inhibition of the pro-inflammatory cytokine interleukin-1 beta (IL-1β) provided the first evidence from a randomized controlled trial (RCT) for a role of inflammation in CVD9, assessed IL-1β activity via measurements of CRP and fibrinogen levels27. The gene discussed is IL1B; the disease is deep vein thrombosis.